Multiomic Health cover
Multiomic Health logo

Multiomic Health

"AI-enabled precision medicine for cardio-renal-metabolic disease"

London
11 - 50 Employees
Biotechnology

Profile written from public sources. Claim it for free

Connect

About Multiomic Health

Multiomic Health develops precision therapeutics for age-related chronic diseases where genetics alone cannot explain continued progression despite standard treatment. Founded in 2021 and based in London, it focuses on cardio-renal-metabolic conditions, particularly chronic kidney disease. The company describes this wider disease group as affecting more than two billion people and costing $2 trillion globally in 2019.

Its platform combines longitudinal patient records, multi-omics data, AI-enabled analysis and experimental biology to identify patient subpopulations with distinct molecular disease drivers. This work supports the development of targeted treatments and associated diagnostics. Multiomic is also building a global cardio-renal-metabolic patient registry, with a stated target of capturing more than 100,000 patients by 2028.

Illustrative visual - may not reflect the actual offering.
Focus
Cardio-renal-metabolic disease
Founded
2021

Scientific and commercial teams

Multiomic combines clinical research, translational science, data science and computational biology with business development and partnership functions. Its operating-team structure brings these specialisms together around its precision-medicine programmes, with scientific advisers contributing additional expertise.

Illustrative visual - may not reflect the actual offering.
Open Positions

Join our team! Explore current opportunities at Multiomic Health.

No open positions at the moment.

Check back soon for new opportunities!